| アブストラクト | BACKGROUND: Schizophrenia (SCZ) patients have high violent and aggressive behavior (VAB) prevalence, causing harm and stigma. The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and triglyceride-glucose index (TyG) show promise for psychiatric disorder prediction, but their links to SCZ patients' VAB risk remain understudied. METHODS: A cross-sectional study included 102 hospitalized SCZ patients from May 2023-October 2024, stratified by Broset Violence Checklist (BVC) into low/medium/high VAB risk groups. Positive and Negative Syndrome Scale (PANSS) quantified psychiatric severity; NHHR and TyG were calculated from venous biochemical indices. Analyses included multivariate logistic regression, mediation analysis (PANSS Scores as mediator), 7 machine learning (ML) models with SHAP interpretation, and FDA Adverse Event Reporting System (FAERS) disproportionality analysis. RESULTS: In fully adjusted models, NHHR and TyG were both negatively associated with VAB risk (NHHR: OR = 0.43, 95%CI:0.20-0.92, p = 0.0285; TyG: OR = 0.29, 95%CI:0.12-0.67, p = 0.0038); further analysis revealed an atypical inverted U-shaped correlation between NHHR and VAB risk, with the inflection point measured at 2.98. Meanwhile, PANSS scores partially mediated the associations between NHHR, TyG and VAB, and TyG had higher mediation proportions (54.2% for BVC scores, 57.8% for VAB risk) than NHHR. In ML-based VAB prediction, LASSO Logistic Regression was the optimal model (Accuracy = 0.8065, highest F1 Score), and SHAP analysis confirmed NHHR and TyG as core predictive features. Additionally, FAERS analysis identified positive metabolic abnormality signals for olanzapine (early-onset adverse events) and quetiapine (late-onset adverse events). CONCLUSION: NHHR and TyG are potential VAB risk biomarkers for SCZ patients, with psychiatric severity mediating their effects. ML and FAERS provide clinical prediction and medication monitoring references. |
|---|
| ジャーナル名 | Lipids in health and disease |
|---|
| Pubmed追加日 | 2025/12/17 |
|---|
| 投稿者 | Qing, Guangwei; Taorigen, Hanggai; Zhou, Yuxin; Wang, Gang |
|---|
| 組織名 | Beijing Key Laboratory of Mental Disorders, National Clinical Research Center for;Mental Disorders & National Center for Mental Disorders, Beijing Anding Hospital,;Capital Medical University, Beijing, China.;Advanced Innovation Center for Human Brain Protection, Capital Medical;University, Beijing, China.;Department of Psychiatry, Jiangxi Mental Hospital & Affiliated Mental Hospital of;Nanchang University, Nanchang, Jiangxi, China.;Nanchang City Key Laboratory of Biological Psychiatry, Jiangxi Provincial;Clinical Research Center on Mental Disorders, Jiangxi Mental Hospital, Nanchang,;Jiangxi, China.;Capital Medical University, Beijing, China. gangwangdoc@ccmu.edu.cn.;University, Beijing, China. gangwangdoc@ccmu.edu.cn. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41402866/ |
|---|
